Menovo released its 2026 interim report on August 12, 2026. The company's total operating revenue was 859 million yuan, net profit attributable to the parent was 63.6891 million yuan, and net cash inflow from operating activities was 25.2359 million yuan. The company's latest asset-liability ratio was 36.07%, gross margin was 29.27%, down 3.18 percentage points from the same period last year, ROE was 2.17%, down 0.01 percentage points from the same period last year. Diluted earnings per share was 0.26 yuan, total asset turnover was 0.18 times, and inventory turnover was 0.68 times. The number of shareholders was 44,100, and the top ten shareholders held 86.1674 million shares, accounting for 35.49% of the total share capital.
Ningbo Menovo Pharm Co LtdInterim report shows net profit and revenue, but gross margin declined; overall financial results mixed.